Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Chemokine Receptor 7 is Essential for Coxiella burnetii Whole-Cell Vaccine Induced Cellular Immunity but Dispensable for Vaccine Mediated Protective Immunity.

Chen C, van Schaik EJ, Gregory AE, Vigil A, Felgner PL, Hendrix LR, Samuel JE.

J Infect Dis. 2019 Apr 2. pii: jiz146. doi: 10.1093/infdis/jiz146. [Epub ahead of print]

PMID:
30938819
2.

Identification of Cytauxzoon felis antigens via protein microarray and assessment of expression library immunization against cytauxzoonosis.

Schreeg ME, Marr HS, Tarigo JL, Sherrill MK, Outi HK, Scholl EH, Bird DM, Vigil A, Hung C, Nakajima R, Liang L, Trieu A, Doolan DL, Thomas JE, Levy MG, Reichard MV, Felgner PL, Cohn LA, Birkenheuer AJ.

Clin Proteomics. 2018 Dec 29;15:44. doi: 10.1186/s12014-018-9218-9. eCollection 2018.

3.

A Petrifying Bowel Movement: a non-operative assistance to nature's resolution of colonic gallstone obstruction?

Shapera E, Miskimins R, Verlanic J, Vigil A.

Acta Gastroenterol Belg. 2017 Apr-Jun;80(2):325-326. No abstract available.

PMID:
29560704
4.

Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses.

Vigil A, Estélles A, Kauvar LM, Johnson SK, Tripp RA, Wittekind M.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02269-17. doi: 10.1128/AAC.02269-17. Print 2018 May.

5.

Improving the explainability of Random Forest classifier - user centered approach.

Petkovic D, Altman R, Wong M, Vigil A.

Pac Symp Biocomput. 2018;23:204-215.

6.

Echocardiographic findings in haemodialysis patients according to their state of hydration.

Cristina Di Gioia M, Gascuena R, Gallar P, Cobo G, Camacho R, Acosta N, Baranyi Z, Rodriguez I, Oliet A, Ortega O, Fernandez I, Mon C, Ortiz M, Manzano MC, Herrero JC, Martinez JI, Palma J, Vigil A.

Nefrologia. 2017 Jan - Feb;37(1):47-53. doi: 10.1016/j.nefro.2016.06.003. Epub 2016 Aug 26. English, Spanish.

7.

Hypogonadism associated with muscle atrophy, physical inactivity and ESA hyporesponsiveness in men undergoing haemodialysis.

Cobo G, Gallar P, Di Gioia C, García Lacalle C, Camacho R, Rodriguez I, Ortega O, Mon C, Vigil A, Lindholm B, Carrero JJ.

Nefrologia. 2017 Jan - Feb;37(1):54-60. doi: 10.1016/j.nefro.2016.04.009. Epub 2016 Aug 21. English, Spanish.

8.

Measurements of Monoclonal Antibody Self-Association Are Correlated with Complex Biophysical Properties.

Geng SB, Wittekind M, Vigil A, Tessier PM.

Mol Pharm. 2016 May 2;13(5):1636-45. doi: 10.1021/acs.molpharmaceut.6b00071. Epub 2016 Apr 19.

PMID:
27045771
9.

Cholesterol management in geriatric patients: new guidelines.

Mahvan TD, Hilaire ML, Vigil A, Mlodinow S.

Consult Pharm. 2015 Feb;30(2):68-76. doi: 10.4140/TCP.n.2015.68. Review.

PMID:
25695413
10.

Glomerulonephritis and cryoglobulinemia: first manifestation of visceral leishmaniasis.

Ortiz M, Mon C, Herrero JC, Oliet A, Rodríguez I, Ortega O, Gallar P, Hinostroza J, Cobo G, del Alamo M, Jiménez J, Torres R, Digiogia C, San Martin J, Vigil AI, Blanco J.

Clin Nephrol. 2015 Jun;83(6):370-7. doi: 10.5414/CN108195.

PMID:
25600859
11.

Clinical determinants of reduced physical activity in hemodialysis and peritoneal dialysis patients.

Cobo G, Gallar P, Gama-Axelsson T, Di Gioia C, Qureshi AR, Camacho R, Vigil A, Heimbürger O, Ortega O, Rodriguez I, Herrero JC, Bárány P, Lindholm B, Stenvinkel P, Carrero JJ.

J Nephrol. 2015 Aug;28(4):503-10. doi: 10.1007/s40620-014-0164-y. Epub 2014 Dec 12.

PMID:
25501981
12.

Lower plasma sodium is associated with a microinflammatory state among patients with advanced chronic kidney disease.

Ortega O, Cobo G, Rodríguez I, Camacho R, Gallar P, Mon C, Herrero JC, Ortiz M, Oliet A, Di Gioia C, Vigil A.

Nephron Clin Pract. 2014;128(3-4):312-8. doi: 10.1159/000368116. Epub 2014 Nov 28.

PMID:
25472577
13.

Geriatric assessment for therapeutic decision-making regarding renal replacement in elderly patients with advanced chronic kidney disease.

Rodriguez Villarreal I, Ortega O, Hinostroza J, Cobo G, Gallar P, Mon C, Herrero JC, Ortiz M, Di Giogia C, Oliet A, Vigil A.

Nephron Clin Pract. 2014;128(1-2):73-8. doi: 10.1159/000363624. Epub 2014 Nov 4.

PMID:
25378358
14.

Mycophenolate in refractory and relapsing lupus nephritis.

Rivera F, Mérida E, Illescas ML, López-Rubio E, Frutos MA, García-Frías P, Ramos C, Sierra M, Baltar J, Lucas J, Oliet A, Vigil A, Fernández-Juárez G, Segarra A, Praga M; Glomerular Spanish Glomerular Study Group (GLOSEN).

Am J Nephrol. 2014;40(2):105-12. doi: 10.1159/000365256. Epub 2014 Jul 30.

PMID:
25096639
15.

Cystatin C as a predictor of mortality and cardiovascular events in a population with chronic kidney disease.

Vigil A, Condés E, Vigil L, Gallar P, Oliet A, Ortega O, Rodriguez I, Ortiz M, Herrero JC, Mon C, Cobo G, Jimenez J.

Int J Nephrol. 2014;2014:127943. doi: 10.1155/2014/127943. Epub 2014 Feb 11.

16.

Identification of seroreactive proteins of Leptospira interrogans serovar copenhageni using a high-density protein microarray approach.

Lessa-Aquino C, Borges Rodrigues C, Pablo J, Sasaki R, Jasinskas A, Liang L, Wunder EA Jr, Ribeiro GS, Vigil A, Galler R, Molina D, Liang X, Reis MG, Ko AI, Medeiros MA, Felgner PL.

PLoS Negl Trop Dis. 2013 Oct 17;7(10):e2499. doi: 10.1371/journal.pntd.0002499. eCollection 2013.

17.

A novel candidate vaccine for cytauxzoonosis inferred from comparative apicomplexan genomics.

Tarigo JL, Scholl EH, McK Bird D, Brown CC, Cohn LA, Dean GA, Levy MG, Doolan DL, Trieu A, Nordone SK, Felgner PL, Vigil A, Birkenheuer AJ.

PLoS One. 2013 Aug 20;8(8):e71233. doi: 10.1371/journal.pone.0071233. eCollection 2013. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/943b121e-343b-4df1-a06b-7f8a205a057d.

18.

Mycophenolate as maintenance therapy for lupus nephritis with impaired renal function.

Rivera F, Illescas ML, López-Rubio E, Fulladosa J, Poveda R, Baltar J, Fernández-Juárez G, Ballarín J, Oliet A, Vigil A, Lucas J, Sierra M, Frutos MA, García-Frías P, Ramos C, Mérida E, Praga M, Segarra A.

Am J Nephrol. 2013;37(6):509-17. doi: 10.1159/000350756. Epub 2013 May 8.

PMID:
23689615
19.

Lack of influence of serum magnesium levels on overall mortality and cardiovascular outcomes in patients with advanced chronic kidney disease.

Ortega O, Rodriguez I, Cobo G, Hinostroza J, Gallar P, Mon C, Ortiz M, Herrero JC, Di Gioia C, Oliet A, Vigil A.

ISRN Nephrol. 2013 Jun 19;2013:191786. doi: 10.5402/2013/191786. eCollection 2013.

20.

Distinct human antibody response to the biological warfare agent Burkholderia mallei.

Varga JJ, Vigil A, DeShazer D, Waag DM, Felgner P, Goldberg JB.

Virulence. 2012 Oct 1;3(6):510-4. doi: 10.4161/viru.22056. Epub 2012 Oct 1.

21.

Mycophenolate as induction therapy in lupus nephritis with renal function impairment.

Rivera F, Fulladosa X, Poveda R, Frutos MA, García-Frías P, Ara J, Illescas L, López-Rubio E, Mérida E, Carreño A, Ballarín J, Fernández-Juárez G, Baltar J, Ramos C, Pons S, Oliet A, Vigil A, Praga M, Segarra A; Spanish Group for the Study of Glomerular Disease (GLOSEN).

Am J Nephrol. 2012;35(5):424-33. doi: 10.1159/000337916. Epub 2012 Apr 20.

PMID:
22517244
22.

Changes in body composition parameters in patients on haemodialysis and peritoneal dialysis.

Di-Gioia MC, Gallar P, Rodríguez I, Laso N, Callejas R, Ortega O, Herrero JC, Vigil A.

Nefrologia. 2012;32(1):108-13. doi: 10.3265/Nefrologia.pre2011.Oct.10938. English, Spanish.

23.

Humoral immune responses to Plasmodium falciparum among HIV-1-infected Kenyan adults.

Nnedu ON, O'Leary MP, Mutua D, Mutai B, Kalantari-Dehaghi M, Jasinskas A, Nakajima-Sasaki R, John-Stewart G, Otieno P, Liang X, Waitumbi J, Kimani F, Camerini D, Felgner PL, Walson JL, Vigil A.

Proteomics Clin Appl. 2011 Dec;5(11-12):613-23. doi: 10.1002/prca.201100021.

24.

Profiling the humoral immune response of acute and chronic Q fever by protein microarray.

Vigil A, Chen C, Jain A, Nakajima-Sasaki R, Jasinskas A, Pablo J, Hendrix LR, Samuel JE, Felgner PL.

Mol Cell Proteomics. 2011 Oct;10(10):M110.006304. doi: 10.1074/mcp.M110.006304. Epub 2011 Aug 4.

25.

[Clinical and biochemical characteristics of predialysis patients in terms of 25 hydroxy vitamin D levels].

Rodríguez Villarreal I, Ortega O, Gallar P, Sánchez M, Callejas R, Gracia C, García la Calle C, Ortiz M, Herrero JC, Mon C, Oliet A, Vigil A.

Nefrologia. 2011;31(2):185-91. doi: 10.3265/Nefrologia.pre2011.Jan.10560. Spanish.

26.

Serum alkaline phosphatase levels and left ventricular diastolic dysfunction in patients with advanced chronic kidney disease.

Ortega O, Rodriguez I, Hinostroza J, Laso N, Callejas R, Gallar P, Mon C, Herrero JC, Ortiz M, Oliet A, Vigil A.

Nephron Extra. 2011 Jan;1(1):283-91. doi: 10.1159/000335303. Epub 2012 Jan 18.

27.

The performance of vasectomy in an urban municipality. Practical considerations for follow-up.

Luján M, Vigil A, Turo J, Pascual C, Nevado M, Martín C, Chiva V.

Arch Esp Urol. 2010 Nov;63(9):797-802.

PMID:
21098904
28.

Identification of immunodominant antigens by probing a whole Chlamydia trachomatis open reading frame proteome microarray using sera from immunized mice.

Cruz-Fisher MI, Cheng C, Sun G, Pal S, Teng A, Molina DM, Kayala MA, Vigil A, Baldi P, Felgner PL, Liang X, de la Maza LM.

Infect Immun. 2011 Jan;79(1):246-57. doi: 10.1128/IAI.00626-10. Epub 2010 Oct 18.

29.

High-throughput prediction of protein antigenicity using protein microarray data.

Magnan CN, Zeller M, Kayala MA, Vigil A, Randall A, Felgner PL, Baldi P.

Bioinformatics. 2010 Dec 1;26(23):2936-43. doi: 10.1093/bioinformatics/btq551. Epub 2010 Oct 7.

30.

Identification of the feline humoral immune response to Bartonella henselae infection by protein microarray.

Vigil A, Ortega R, Jain A, Nakajima-Sasaki R, Tan X, Chomel BB, Kasten RW, Koehler JE, Felgner PL.

PLoS One. 2010 Jul 6;5(7):e11447. doi: 10.1371/journal.pone.0011447.

31.

Vitamin D deficiency in dialysis patients: effect of dialysis modality and implications on outcome.

Gracia-Iguacel C, Gallar P, Qureshi AR, Ortega O, Mon C, Ortiz M, Villarreal I, Garcia-Lacalle C, Olieta A, Sánchez M, Herrero JC, Vigil A, Lindholm B, Carrero JJ.

J Ren Nutr. 2010 Nov;20(6):359-67. doi: 10.1053/j.jrn.2010.03.005. Epub 2010 May 26.

PMID:
20537919
32.

[Vascular access models cause heterogeneous results in the centres of one community].

Gruss E, Portolés J, Caro P, Merino JL, López-Sánchez P, Tato A, Rubio E, Vigil A, Albalate M, Hernández J, Fernández M, Sanz P; Grupo de Estudio del Acceso Vascular (AVE).

Nefrologia. 2010;30(3):310-6. doi: 10.3265/Nefrologia.pre2010.Apr.10359. Epub 2010 Apr 14. Spanish.

33.

Genome-wide profiling of humoral immune response to Coxiella burnetii infection by protein microarray.

Vigil A, Ortega R, Nakajima-Sasaki R, Pablo J, Molina DM, Chao CC, Chen HW, Ching WM, Felgner PL.

Proteomics. 2010 Jun;10(12):2259-69. doi: 10.1002/pmic.201000064.

34.

Defining the humoral immune response to infectious agents using high-density protein microarrays.

Vigil A, Davies DH, Felgner PL.

Future Microbiol. 2010 Feb;5(2):241-51. doi: 10.2217/fmb.09.127. Review.

35.

Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy.

Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, Baltar J, Fernández-Fresnedo G, Martín C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P, Fernández-Juárez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernández-Vega F, Praga M; Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología.

J Am Soc Nephrol. 2010 Apr;21(4):697-704. doi: 10.1681/ASN.2009080861. Epub 2010 Jan 28.

36.

A Burkholderia pseudomallei protein microarray reveals serodiagnostic and cross-reactive antigens.

Felgner PL, Kayala MA, Vigil A, Burk C, Nakajima-Sasaki R, Pablo J, Molina DM, Hirst S, Chew JS, Wang D, Tan G, Duffield M, Yang R, Neel J, Chantratita N, Bancroft G, Lertmemongkolchai G, Davies DH, Baldi P, Peacock S, Titball RW.

Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13499-504. doi: 10.1073/pnas.0812080106. Epub 2009 Jul 28.

37.

Strict volume control and longitudinal changes in cardiac biomarker levels in hemodialysis patients.

Ortega O, Rodriguez I, Gracia C, Sanchez M, Lentisco C, Mon C, Gallar P, Ortiz M, Herrero JC, Oliet A, Vigil A.

Nephron Clin Pract. 2009;113(2):c96-103. doi: 10.1159/000228541. Epub 2009 Jul 14.

PMID:
19602905
38.

Genetically engineered Newcastle disease virus for malignant melanoma therapy.

Zamarin D, Vigil A, Kelly K, García-Sastre A, Fong Y.

Gene Ther. 2009 Jun;16(6):796-804. doi: 10.1038/gt.2009.14. Epub 2009 Feb 26.

39.

Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses.

Zamarin D, Martínez-Sobrido L, Kelly K, Mansour M, Sheng G, Vigil A, García-Sastre A, Palese P, Fong Y.

Mol Ther. 2009 Apr;17(4):697-706. doi: 10.1038/mt.2008.286. Epub 2009 Feb 10.

40.

Recombinant Newcastle disease virus as a vaccine vector for cancer therapy.

Vigil A, Martinez O, Chua MA, García-Sastre A.

Mol Ther. 2008 Nov;16(11):1883-90. doi: 10.1038/mt.2008.181. Epub 2008 Aug 19.

41.

[Sclerosing encapsulating peritonitis: a latent threat. Changes of posture in surgery treatment].

Herrero JC, Molina A, Lentisco C, García C, Ortiz M, Mon C, Ortega O, Rodríguez I, Oliet A, Vigil A, Gallar P.

Nefrologia. 2007;27(6):729-36. Spanish.

42.

Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus.

Vigil A, Park MS, Martinez O, Chua MA, Xiao S, Cros JF, Martínez-Sobrido L, Woo SL, García-Sastre A.

Cancer Res. 2007 Sep 1;67(17):8285-92.

43.

Two-year experience with telemedicine in the follow-up of patients in home peritoneal dialysis.

Gallar P, Vigil A, Rodriguez I, Ortega O, Gutierrez M, Hurtado J, Oliet A, Ortiz M, Mon C, Herrero JC, Lentisco C.

J Telemed Telecare. 2007;13(6):288-92.

PMID:
17785025
44.

[Factors which influence phosphorus removal in hemodialysis].

Gallar P, Ortiz M, Ortega O, Rodríguez I, Seijas V, Carreño A, Oliet A, Vigil A.

Nefrologia. 2007;27(1):46-52. Spanish.

45.

Treatment of hirudin overdosage in a dialysis patient with heparin-induced thrombocytopenia with mixed hemodialysis and hemofiltration treatment.

Mon C, Moreno G, Ortiz M, Diaz R, Herrero JC, Oliet A, Rodriguez I, Ortega O, Gallar P, Vigil A.

Clin Nephrol. 2006 Oct;66(4):302-5.

PMID:
17063999
46.

[Telemedicine and follow up of peritoneal dialysis patients].

Gallar P, Gutiérrez M, Ortega O, Rodríguez I, Oliet A, Herrero JC, Mon C, Ortiz M, Molina A, Vigil A.

Nefrologia. 2006;26(3):365-71. Spanish.

47.

Association between C-reactive protein levels and N-terminal pro-B-type natriuretic peptide in pre-dialysis patients.

Ortega O, Gallar P, Muñoz M, Rodríguez I, Carreño A, Ortiz M, Molina A, Oliet A, Lozano L, Vigil A.

Nephron Clin Pract. 2004;97(4):c125-30.

PMID:
15331941
48.

[Peritoneal dialysis in acute renal failure secondary to cholesterol crystal embolism].

Carreño A, Gallar P, Ortega O, Vigil AI.

Nefrologia. 2003;23(1):91. Spanish. No abstract available.

49.

Significance of high C-reactive protein levels in pre-dialysis patients.

Ortega O, Rodriguez I, Gallar P, Carreño A, Ortiz M, Espejo B, Jimenez J, Gutierrez M, Oliet A, Vigil A.

Nephrol Dial Transplant. 2002 Jun;17(6):1105-9.

PMID:
12032204
50.

[Automated peritoneal dialysis: impact on residual kidney function and peritoneal membrane permeability].

Gallar P, Ortega O, Gutiérrez M, Carreño A, Domínguez-Gil B, Hilara L, Oliet A, Rodríguez I, Giménez E, Vigil A.

Nefrologia. 2001 Mar-Apr;21(2):200-3. Spanish. No abstract available.

Supplemental Content

Support Center